New potential selective estrogen receptor modulators in traditional Chinese medicine for treating menopausal syndrome.
SERM
estrogen receptor
menopausal syndrome
traditional Chinese medicine
women
Journal
Phytotherapy research : PTR
ISSN: 1099-1573
Titre abrégé: Phytother Res
Pays: England
ID NLM: 8904486
Informations de publication
Date de publication:
09 Aug 2024
09 Aug 2024
Historique:
revised:
19
05
2024
received:
20
11
2023
accepted:
23
06
2024
medline:
9
8
2024
pubmed:
9
8
2024
entrez:
9
8
2024
Statut:
aheadofprint
Résumé
Women go through several predictable conditions and symptoms during menopause that are caused by age, changes in sex hormone levels, and other factors. Conventional menopause hormone therapy has raised serious concerns about the increased risks of cancers, blood clots, depression, etc. Selective estrogen receptor modulators (SERMs) that can be both agonists and antagonists of estrogen receptors in a tissue-specific manner are being developed to reduce the health concerns associated with menopause hormone therapy. Here, we have searched the Chinese national traditional Chinese medicine (TCM) patent database to identify potential SERM-like compounds with reduced health risks. TCM has been widely used for treating complex symptoms associated with menopause syndrome and thus can be a particularly rich source for pharmaceutical alternatives with SERM properties. After extensive literature review and molecular simulation, we conclude that protopanaxatriol, paeoniflorin, astragalin, catalpol, and hyperoside among others may be particularly promising as SERM-like compounds in treating the menopausal syndrome. Compounds in TCM hold promise in yielding comparable outcomes to hormone therapy but with reduced associated risks, thus presenting promising avenues for their clinical applications.
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Natural Science Foundation of Liaoning Province
ID : 2021-BS-129
Organisme : National Natural Science Foundation of China
ID : 31971335
Organisme : National Natural Science Foundation of China
ID : 82104260
Informations de copyright
© 2024 John Wiley & Sons, Ltd.
Références
Abdel‐Qadir, H., Amir, E., Fischer, H. D., Fu, L., Austin, P. C., Harvey, P. J., Rochon, P. A., Lee, D. S., & Anderson, G. M. (2016). The risk of myocardial infarction with aromatase inhibitors relative to tamoxifen in post‐menopausal women with early stage breast cancer. European Journal of Cancer, 68, 11–21. https://doi.org/10.1016/j.ejca.2016.08.022
Alrefaie, Z. A., Amin, H. A., & Elgayed, S. H. (2011). Estrogenicity of outer scales of onion on uteri of immature mice. Canadian Journal of Physiology and Pharmacology, 89(11), 829–835. https://doi.org/10.1139/y11-085
Anthamatten, A., & Parish, A. (2019). Clinical update on osteoporosis. Journal of Midwifery & Women's Health, 64(3), 265–275. https://doi.org/10.1111/jmwh.12954
Artero, A., Tarín, J. J., & Cano, A. (2012). The adverse effects of estrogen and selective estrogen receptor modulators on hemostasis and thrombosis. Seminars in Thrombosis and Hemostasis, 38(8), 797–807. https://doi.org/10.1055/s-0032-1328883
Asma, N., Fatemeh, Z., Atefeh, S., & Sanaz, A. (2019). Amelioration by quercetin of insulin resistance and uterine GLUT4 and ERα gene expression in rats with polycystic ovary syndrome (PCOS). Reproduction, Fertility and Development, 31, 31–323.
Baek, J. M., Kim, H. J., Nam, M. W., Park, H. J., Yeon, S. H., Oh, M. H., Yoon, J. S., Kwon, H. J., Lee, K. P., & Lim, J. H. (2019). Standardized seed extract of Quisqualis indica (HU‐033) attenuates testosterone propionate‐induced benign prostatic hyperplasia via α1‐adrenergic receptors and androgen/estrogen signaling. Preventive Nutrition and Food Science, 24(4), 492–497. https://doi.org/10.3746/pnf.2019.24.4.492
Borgo, M. V., Lopes, A. B., Gouvêa, S. A., Romero, W. G., Moyses, M. R., Bissoli, N. S., & Abreu, G. R. (2011). Effect of tamoxifen on the coronary vascular reactivity of spontaneously hypertensive female rats. Brazilian Journal of Medical and Biological Research, 44(8), 786–792. https://doi.org/10.1590/s0100-879x2011007500099
Buijs, S. M., Koolen, S. L. W., Mathijssen, R. H. J., & Jager, A. (2024). Tamoxifen dose De‐escalation: An effective strategy for reducing adverse effects? Drugs, 84, 385–401. https://doi.org/10.1007/s40265-024-02010-x
Cao, L. H., Qiao, J. Y., Huang, H. Y., Fang, X. Y., Zhang, R., Miao, M. S., & Li, X. M. (2019). PI3K‐AKT signaling activation and icariin: The potential effects on the Perimenopausal depression‐like rat model. Molecules, 24, 203700. https://doi.org/10.3390/molecules24203700
Ceballos, C., Ribes, C., Amado, J. A., de Mier, I., de Rozas, L. S., & Berrazueta, J. R. (2001). Venous endothelial function in postmenopausal women after six months of tibolone therapy. Maturitas, 39(1), 63–70. https://doi.org/10.1016/s0378-5122(00)00217-6
Chan, C. W. H., Law, B. M. H., So, W. K. W., Chow, K. M., & Waye, M. M. Y. (2020). Pharmacogenomics of breast cancer: Highlighting CYP2D6 and tamoxifen. Journal of Cancer Research and Clinical Oncology, 146(6), 1395–1404. https://doi.org/10.1007/s00432-020-03206-w
Chen, M. Y., Tsai, B. C., Kuo, W. W., Kuo, C. H., Lin, Y. M., Hsieh, D. J., Pai, P. Y., Liao, S. C., Huang, S. E., Lee, S. D., & Huang, C. Y. (2023). Diosgenin attenuates myocardial cell apoptosis triggered by oxidative stress through estrogen receptor to activate the PI3K/Akt and ERK axes. The American Journal of Chinese Medicine, 51(5), 1211–1232. https://doi.org/10.1142/s0192415x23500556
Chen, Q., Qi, X., Zhang, W., Zhang, Y., Bi, Y., Meng, Q., Bian, H., & Li, Y. (2021). Catalpol inhibits macrophage polarization and prevents postmenopausal atherosclerosis through regulating estrogen receptor alpha. Frontiers in Pharmacology, 12, 655081. https://doi.org/10.3389/fphar.2021.655081
Chen, W. F., Gao, Q. G., Dai, Z. J., Kung, A. W., Guo, D. A., & Wong, M. S. (2012). Estrogenic effects of ginsenoside Rg1 in endometrial cells in vitro were not observed in immature CD‐1 mice or ovariectomized mice model. Menopause, 19(9), 1052–1061. https://doi.org/10.1097/gme.0b013e318250361c
Chen, X., Zhang, S., Chen, X., Hu, Y., Wu, J., Chen, S., Chang, J., Wang, G., & Gao, Y. (2017). Emodin promotes the osteogenesis of MC3T3‐E1 cells via BMP‐9/Smad pathway and exerts a preventive effect in ovariectomized rats. Acta Biochimica et Biophysica Sinica (Shanghai), 49(10), 867–878. https://doi.org/10.1093/abbs/gmx087
Chen, Y., Li, Y. Q., Fang, J. Y., Li, P., & Li, F. (2020). Establishment of the concurrent experimental model of osteoporosis combined with Alzheimer's disease in rat and the dual‐effects of echinacoside and acteoside from Cistanche tubulosa. Journal of Ethnopharmacology, 257, 112834. https://doi.org/10.1016/j.jep.2020.112834
Choi, B. G., Vilahur, G., Zafar, M. U., Cardoso, L., Yadegar, D., Ibanez, B., Tunstead, J., Viles‐Gonzalez, J. F., Schaffler, M. B., Fuster, V., & Badimon, J. J. (2008). Selective estrogen receptor modulation influences atherosclerotic plaque composition in a rabbit menopause model. Atherosclerosis, 201(1), 76–84. https://doi.org/10.1016/j.atherosclerosis.2008.01.017
Choi, E., Lee, J. K., Baek, J. K., Chung, Y., Kim, H., Yun, B. H., & Seo, S. K. (2024). Hormone replacement therapy and breast cancer incidence in Korean women. Maturitas, 183, 107946. https://doi.org/10.1016/j.maturitas.2024.107946
Choi, K. O., Lee, I., Paik, S. Y., Kim, D. E., Lim, J. D., Kang, W. S., & Ko, S. (2012). Ultrafine Angelica gigas powder normalizes ovarian hormone levels and has antiosteoporosis properties in ovariectomized rats: Particle size effect. Journal of Medicinal Food, 15(10), 863–872. https://doi.org/10.1089/jmf.2011.2047
Clarkson, T. B., Ethun, K. F., Pajewski, N. M., Golden, D., Floyd, E., & Appt, S. E. (2014). Effects of bazedoxifene, conjugated equine estrogens, and a tissue‐selective estrogen complex containing both bazedoxifene and conjugated equine estrogens on cerebral artery atherosclerosis in postmenopausal monkeys. Menopause, 21(1), 8–14. https://doi.org/10.1097/GME.0b013e31829370e5
Clemett, D., & Spencer, C. M. (2000). Raloxifene: A review of its use in postmenopausal osteoporosis. Drugs, 60(2), 379–411. https://doi.org/10.2165/00003495-200060020-00013
Colditz, G. A., Hankinson, S. E., Hunter, D. J., Willett, W. C., Manson, J. E., Stampfer, M. J., Hennekens, C., Rosner, B., & Speizer, F. E. (1995). The use of estrogens and progestins and the risk of breast cancer in postmenopausal women. The New England Journal of Medicine, 332(24), 1589–1593. https://doi.org/10.1056/nejm199506153322401
Comini, A. C. M., Carvalho, B. M., Moreira, M. J. B., Reis, P. C. A., Colapietro, L., Northern, J., & Batalini, F. (2023). Safety and serum estradiol levels in hormonal treatments for vulvovaginal atrophy in breast cancer survivors: A systematic review and meta‐analysis. Clinical Breast Cancer, 23(8), 835–846. https://doi.org/10.1016/j.clbc.2023.08.003
Corbi, G., Nobile, V., Conti, V., Cannavo, A., Sorrenti, V., Medoro, A., Scapagnini, G., & Davinelli, S. (2023). Equol and resveratrol improve bone turnover biomarkers in postmenopausal women: A clinical trial. International Journal of Molecular Sciences, 24(15), 12063. https://doi.org/10.3390/ijms241512063
Daniels, L. B., Grady, D., Mosca, L., Collins, P., Mitlak, B. H., Amewou‐Atisso, M. G., Wenger, N. K., & Barrett‐Connor, E. (2013). Is diabetes mellitus a heart disease equivalent in women? Results from an international study of postmenopausal women in the Raloxifene use for the heart (RUTH) trial. Circulation. Cardiovascular Quality and Outcomes, 6(2), 164–170. https://doi.org/10.1161/circoutcomes.112.966986
Davis, A. M., Ellersieck, M. R., Grimm, K. M., & Rosenfeld, C. S. (2006). The effects of the selective estrogen receptor modulators, methyl‐piperidino‐pyrazole (MPP), and raloxifene in normal and cancerous endometrial cell lines and in the murine uterus. Molecular Reproduction and Development, 73(8), 1034–1044. https://doi.org/10.1002/mrd.20520
Davis, S. R., & Baber, R. J. (2022). Treating menopause ‐ MHT and beyond. Nature Reviews. Endocrinology, 18(8), 490–502. https://doi.org/10.1038/s41574-022-00685-4
de Villiers, T. J. (2009). Clinical issues regarding cardiovascular disease and selective estrogen receptor modulators in postmenopausal women. Climacteric, 12(Suppl 1), 108–111. https://doi.org/10.1080/13697130903010953
de Villiers, T. J., Altomare, C., Particco, M., & Gambacciani, M. (2019). Effects of ospemifene on bone in postmenopausal women. Climacteric, 22(5), 442–447. https://doi.org/10.1080/13697137.2019.1631789
Di Donato, V., Schiavi, M. C., Iacobelli, V., D'Oria, O., Kontopantelis, E., Simoncini, T., Muzii, L., & Benedetti Panici, P. (2019). Ospemifene for the treatment of vulvar and vaginal atrophy: A meta‐analysis of randomized trials. Part II: Evaluation of tolerability and safety. Maturitas, 121, 93–100. https://doi.org/10.1016/j.maturitas.2018.11.017
Donnapee, S., Li, J., Yang, X., Ge, A. H., Donkor, P. O., Gao, X. M., & Chang, Y. X. (2014). Cuscuta chinensis Lam.: A systematic review on ethnopharmacology, phytochemistry and pharmacology of an important traditional herbal medicine. Journal of Ethnopharmacology, 157, 292–308. https://doi.org/10.1016/j.jep.2014.09.032
Eastell, R., Rosen, C. J., Black, D. M., Cheung, A. M., Murad, M. H., & Shoback, D. (2019). Pharmacological management of osteoporosis in postmenopausal women: An Endocrine Society* clinical practice guideline. The Journal of Clinical Endocrinology and Metabolism, 104(5), 1595–1622. https://doi.org/10.1210/jc.2019-00221
Ebrahimi, M. N., Khaksari, M., Sepehri, G., Karam, G. A., Raji‐Amirhasani, A., & Azizian, H. (2020). The effects of alone and combination tamoxifen, raloxifene and estrogen on lipid profile and atherogenic index of ovariectomized type 2 diabetic rats. Life Sciences, 263, 118573. https://doi.org/10.1016/j.lfs.2020.118573
Ensrud, K., LaCroix, A., Thompson, J. R., Thompson, D. D., Eastell, R., Reid, D. M., Vukicevic, S., Cauley, J., Barrett‐Connor, E., Armstrong, R., Welty, F., & Cummings, S. (2010). Lasofoxifene and cardiovascular events in postmenopausal women with osteoporosis: Five‐year results from the postmenopausal evaluation and risk reduction with Lasofoxifene (PEARL) trial. Circulation, 122(17), 1716–1724. https://doi.org/10.1161/circulationaha.109.924571
Fu, L., Zhou, L., Geng, S., Li, M., Lu, W., Lu, Y., Feng, Z., & Zhou, X. (2020). Catalpol coordinately regulates phase I and II detoxification enzymes of Triptolide through CAR and NRF2 pathways to reduce Triptolide‐induced hepatotoxicity. Biomedicine & Pharmacotherapy, 129, 110379. https://doi.org/10.1016/j.biopha.2020.110379
Gabriel, E. M., & Jatoi, I. (2012). Breast cancer chemoprevention. Expert Review of Anticancer Therapy, 12(2), 223–228. https://doi.org/10.1586/era.11.206
Gambacciani, M., & Levancini, M. (2014). Management of postmenopausal osteoporosis and the prevention of fractures. Panminerva Medica, 56(2), 115–131.
Gao, Q. G., Chan, H. Y., Man, C. W., & Wong, M. S. (2014). Differential ERα‐mediated rapid estrogenic actions of ginsenoside Rg1 and estren in human breast cancer MCF‐7 cells. The Journal of Steroid Biochemistry and Molecular Biology, 141, 104–112. https://doi.org/10.1016/j.jsbmb.2014.01.014
Gao, Q. G., Zhou, L. P., Lee, V. H., Chan, H. Y., Man, C. W., & Wong, M. S. (2019). Ginsenoside Rg1 activates ligand‐independent estrogenic effects via rapid estrogen receptor signaling pathway. Journal of Ginseng Research, 43(4), 527–538. https://doi.org/10.1016/j.jgr.2018.03.004
Gharehbagni, M., Sendag, F., Akercan, F., Zeybek, B., Sezer, E., Terek, M. C., & Karadadas, N. (2010). Effects of tamoxifen on tissue nitrite/nitrate levels and plasma lipid peroxidation in female rats. Clinical and Experimental Obstetrics & Gynecology, 37(2), 112–114.
Goldstein, S. R., Bachmann, G. A., Koninckx, P. R., Lin, V. H., Portman, D. J., & Ylikorkala, O. (2014). Ospemifene 12‐month safety and efficacy in postmenopausal women with vulvar and vaginal atrophy. Climacteric, 17(2), 173–182. https://doi.org/10.3109/13697137.2013.834493
Goldstein, S. R., Duvernoy, C. S., Calaf, J., Adachi, J. D., Mershon, J. L., Dowsett, S. A., Agnusdei, D., & Stuenkel, C. A. (2009). Raloxifene use in clinical practice: Efficacy and safety. Menopause, 16(2), 413–421. https://doi.org/10.1097/gme.0b013e3181883dae
Grub, J., Willi, J., Süss, H., & Ehlert, U. (2024). The role of estrogen receptor gene polymorphisms in menopausal symptoms and estradiol levels in perimenopausal women ‐ findings from the Swiss perimenopause study. Maturitas, 183, 107942. https://doi.org/10.1016/j.maturitas.2024.107942
Guo, K., Wang, T., Luo, E., Leng, X., & Yao, B. (2021). Use of network pharmacology and molecular docking technology to analyze the mechanism of action of velvet antler in the treatment of postmenopausal osteoporosis. Evidence‐Based Complementary and Alternative Medicine, 2021, 7144529. https://doi.org/10.1155/2021/7144529
Guzzo, J. A. (2000). Selective estrogen receptor modulators–A new age of estrogens in cardiovascular disease? Clinical Cardiology, 23(1), 15–17. https://doi.org/10.1002/clc.4960230104
Han, S., Cicek, A. F., Tokmak, A., Yildirir Ustun, T., Ercan Gokay, N., Uludag, M. O., & Demirel, M. A. (2021). Effects of resveratrol on receptor expression and serum levels of estrogen and progesterone in the rat Endometritis model. Reproductive Sciences, 28(9), 2610–2622. https://doi.org/10.1007/s43032-021-00586-3
Hosfield, D. J., Weber, S., Li, N. S., Sauvage, M., Joiner, C. F., Hancock, G. R., Sullivan, E. A., Ndukwe, E., Han, R., Cush, S., Lainé, M., Mader, S. C., Greene, G. L., & Fanning, S. W. (2022). Stereospecific lasofoxifene derivatives reveal the interplay between estrogen receptor alpha stability and antagonistic activity in ESR1 mutant breast cancer cells. eLife, 11, e72512. https://doi.org/10.7554/eLife.72512
Huang, H., Zhao, J., Jiang, L., Xie, Y., Xia, Y., Lv, R., & Dong, L. (2015). Paeoniflorin improves menopause depression in ovariectomized rats under chronic unpredictable mild stress. International Journal of Clinical and Experimental Medicine, 8(4), 5103–5111.
Huang, J. P., Hsu, S. C., Li, D. E., Chen, K. H., Kuo, C. Y., & Hung, L. M. (2018). Resveratrol mitigates high‐fat diet‐induced vascular dysfunction by activating the Akt/eNOS/NO and Sirt1/ER pathway. Journal of Cardiovascular Pharmacology, 72(5), 231–241. https://doi.org/10.1097/fjc.0000000000000621
Huang, P. H., Huang, C. Y., Chen, M. C., Lee, Y. T., Yue, C. H., Wang, H. Y., & Lin, H. (2013). Emodin and aloe‐Emodin suppress breast cancer cell proliferation through ER α inhibition. Evidence‐Based Complementary and Alternative Medicine, 2013, 376123. https://doi.org/10.1155/2013/376123
Jeon, J., Kim, S. E., Lee, D. Y., & Choi, D. (2020). Factors associated with endometrial pathology during tamoxifen therapy in women with breast cancer: A retrospective analysis of 821 biopsies. Breast Cancer Research and Treatment, 179(1), 125–130. https://doi.org/10.1007/s10549-019-05448-w
Jiang, J., He, J., Xiao, S., Shenyuan, J., Chen, T., & Pei, D. (2023). Screening of superior anti‐osteoporotic flavonoids from Epimedii folium with dual effects of reversing iron overload and promoting osteogenesis. Biomedical Chromatography, 37, e5686. https://doi.org/10.1002/bmc.5686
Jiang, Z., Deng, L., Li, M., Alonge, E., Wang, Y., & Wang, Y. (2024). Ginsenoside Rg1 modulates PI3K/AKT pathway for enhanced osteogenesis via GPER. Phytomedicine, 124, 155284. https://doi.org/10.1016/j.phymed.2023.155284
Jick, H., Derby, L. E., Myers, M. W., Vasilakis, C., & Newton, K. M. (1996). Risk of hospital admission for idiopathic venous thromboembolism among users of postmenopausal oestrogens. Lancet, 348(9033), 981–983. https://doi.org/10.1016/s0140-6736(96)07114-0
Jin, M. L., Yang, L., & Jeong, K. W. (2022). SETD1A‐SOX2 axis is involved in tamoxifen resistance in estrogen receptor α‐positive breast cancer cells. Theranostics, 12(13), 5761–5775. https://doi.org/10.7150/thno.72599
Jing, Y., Hu, T., Yuan, J., Liu, Z., Tao, M., Ou, M., Cheng, X., Cheng, W., Yi, Y., & Xiong, Q. (2023). Resveratrol protects against postmenopausal atherosclerosis progression through reducing PCSK9 expression via the regulation of the ERα‐mediated signaling pathway. Biochemical Pharmacology, 211, 115541. https://doi.org/10.1016/j.bcp.2023.115541
Johnson, A., Roberts, L., & Elkins, G. (2019). Complementary and alternative medicine for menopause. Journal of Evidence‐Based Integrative Medicine, 24, 2515690x19829380. https://doi.org/10.1177/2515690x19829380
Jordan, V. C. (2008). The rise of raloxifene and the fall of invasive breast cancer. Journal of the National Cancer Institute, 100(12), 831–833. https://doi.org/10.1093/jnci/djn177
Jordan, V. C., Gapstur, S., & Morrow, M. (2001). Selective estrogen receptor modulation and reduction in risk of breast cancer, osteoporosis, and coronary heart disease. Journal of the National Cancer Institute, 93(19), 1449–1457. https://doi.org/10.1093/jnci/93.19.1449
Kang, H. K., Choi, Y. H., Kwon, H., Lee, S. B., Kim, D. H., Sung, C. K., Park, Y. I., & Dong, M. S. (2012). Estrogenic/antiestrogenic activities of a Epimedium koreanum extract and its major components: In vitro and in vivo studies. Food and Chemical Toxicology, 50(8), 2751–2759. https://doi.org/10.1016/j.fct.2012.05.017
Kangas, L., Härkönen, P., Väänänen, K., & Peng, Z. (2014). Effects of the selective estrogen receptor modulator ospemifene on bone in rats. Hormone and Metabolic Research, 46(1), 27–35. https://doi.org/10.1055/s-0033-1355356
Kangas, L., & Unkila, M. (2013). Tissue selectivity of ospemifene: Pharmacologic profile and clinical implications. Steroids, 78(12–13), 1273–1280. https://doi.org/10.1016/j.steroids.2013.09.003
Kastrati, I., Edirisinghe, P. D., Hemachandra, L. P., Chandrasena, E. R., Choi, J., Wang, Y. T., Bolton, J. L., & Thatcher, G. R. (2011). Raloxifene and desmethylarzoxifene block estrogen‐induced malignant transformation of human breast epithelial cells. PLoS One, 6(11), e27876. https://doi.org/10.1371/journal.pone.0027876
Kasule, S. N., Gupta, S., Patron, R. L., Grill, M. F., & Vikram, H. R. (2023). Neuroinvasive West Nile virus infection in solid organ transplant recipients. Transplant Infectious Disease, 25(1), e14004. https://doi.org/10.1111/tid.14004
Kikegawa, M., Nakajima, A., Yu, J., Asai, M., Uesawa, Y., & Sone, H. (2022). Molecular profiling of ginsenoside metabolites to identify estrogen receptor alpha activity. Gene, 813, 146108. https://doi.org/10.1016/j.gene.2021.146108
Kim, Y., Tian, Y., Yang, J., Huser, V., Jin, P., Lambert, C. G., Park, H., You, S. C., Park, R. W., Rijnbeek, P. R., Van Zandt, M., Reich, C., Vashisht, R., Wu, Y., Duke, J., Hripcsak, G., Madigan, D., Shah, N. H., Ryan, P. B., … Suchard, M. A. (2020). Comparative safety and effectiveness of alendronate versus raloxifene in women with osteoporosis. Scientific Reports, 10(1), 11115. https://doi.org/10.1038/s41598-020-68037-8
Ko, B. S., Lee, H. W., Kim, D. S., Kang, S., Ryuk, J. A., & Park, S. (2014). Supplementing with Opuntia ficus‐indica Mill and Dioscorea nipponica Makino extracts synergistically attenuates menopausal symptoms in estrogen‐deficient rats. Journal of Ethnopharmacology, 155(1), 267–276. https://doi.org/10.1016/j.jep.2014.05.020
Ko, S. S., & Jordan, V. C. (2011). Treatment of osteoporosis and reduction in risk of invasive breast cancer in postmenopausal women with raloxifene. Expert Opinion on Pharmacotherapy, 12(4), 657–674. https://doi.org/10.1517/14656566.2011.557360
Lai, N., Zhang, J., Ma, X., Wang, B., Miao, X., Wang, Z., Guo, Y., Wang, L., Yao, C., Li, X., & Jiang, G. (2015). Regulatory effect of catalpol on Th1/Th2 cells in mice with bone loss induced by estrogen deficiency. American Journal of Reproductive Immunology, 74(6), 487–498. https://doi.org/10.1111/aji.12423
Lainé, M., Fanning, S. W., Chang, Y. F., Green, B., Greene, M. E., Komm, B., Kurleto, J. D., Phung, L., & Greene, G. L. (2021). Lasofoxifene as a potential treatment for therapy‐resistant ER‐positive metastatic breast cancer. Breast Cancer Research, 23(1), 54. https://doi.org/10.1186/s13058-021-01431-w
Lama, A., Santoro, A., Corrado, B., Pirozzi, C., Paciello, O., Pagano, T. B., Russo, S., Calignano, A., Mattace Raso, G., & Meli, R. (2017). Extracorporeal shock waves alone or combined with raloxifene promote bone formation and suppress resorption in ovariectomized rats. PLoS One, 12(2), e0171276. https://doi.org/10.1371/journal.pone.0171276
Lee, H. G., Hur, J., Won, J. P., & Seo, H. G. (2024). Ginseng (Panax ginseng) leaf extract modulates the expression of heme oxygenase‐1 to attenuate osteoclast differentiation. Fitoterapia, 173, 105831. https://doi.org/10.1016/j.fitote.2024.105831
Lee, M., Piao, J., & Jeon, M. J. (2020). Risk factors associated with endometrial pathology in premenopausal breast cancer patients treated with tamoxifen. Yonsei Medical Journal, 61(4), 317–322. https://doi.org/10.3349/ymj.2020.61.4.317
Li, F., Yang, X., Bi, J., Yang, Z., & Zhang, C. (2016). Antiosteoporotic activity of Du‐Zhong‐Wan water extract in ovariectomized rats. Pharmaceutical Biology, 54(9), 1857–1864. https://doi.org/10.3109/13880209.2015.1133657
Li, F., Yang, X., Yang, Y., Guo, C., Zhang, C., Yang, Z., & Li, P. (2013). Antiosteoporotic activity of echinacoside in ovariectomized rats. Phytomedicine, 20(6), 549–557. https://doi.org/10.1016/j.phymed.2013.01.001
Li, J., Zou, Z., Su, X., Xu, P., Du, H., Li, Y., Li, Z., Guo, L., Lin, N., & Xu, Y. (2024). Cistanche deserticola improves ovariectomized‐induced osteoporosis mainly by regulating lipid metabolism: Insights from serum metabolomics using UPLC/Q‐TOF‐MS. Journal of Ethnopharmacology, 322, 117570. https://doi.org/10.1016/j.jep.2023.117570
Li, X., Chen, R., Lei, X., Wang, P., Zhu, X., Zhang, R., & Yang, L. (2021). Quercetin regulates ERα mediated differentiation of BMSCs through circular RNA. Gene, 769, 145172. https://doi.org/10.1016/j.gene.2020.145172
Lim, D. W., & Kim, Y. T. (2014). Anti‐osteoporotic effects of Angelica sinensis (Oliv.) Diels extract on ovariectomized rats and its oral toxicity in rats. Nutrients, 6(10), 4362–4372. https://doi.org/10.3390/nu6104362
Lin, J., Zhu, J., Wang, Y., Zhang, N., Gober, H. J., Qiu, X., Li, D., & Wang, L. (2017). Chinese single herbs and active ingredients for postmenopausal osteoporosis: From preclinical evidence to action mechanism. Bioscience Trends, 11(5), 496–506. https://doi.org/10.5582/bst.2017.01216
Liu, G. F., Wang, Z. Q., Liu, L., Zhang, B. T., Miao, Y. Y., & Yu, S. N. (2018). A network meta‐analysis on the short‐term efficacy and adverse events of different anti‐osteoporosis drugs for the treatment of postmenopausal osteoporosis. Journal of Cellular Biochemistry, 119(6), 4469–4481. https://doi.org/10.1002/jcb.26550
Liu, H., Lu, X., Hu, Y., & Fan, X. (2020). Chemical constituents of Panax ginseng and Panax notoginseng explain why they differ in therapeutic efficacy. Pharmacological Research, 161, 105263. https://doi.org/10.1016/j.phrs.2020.105263
Liu, H., Zhong, L., Dai, Q., Zhang, Y., & Yang, J. (2022). Astragalin alleviates cognitive deficits and neuronal damage in SAMP8 mice through upregulating estrogen receptor expression. Metabolic Brain Disease, 37(8), 3033–3046. https://doi.org/10.1007/s11011-022-01045-x
Liu, J., Ding, S., Yang, L., Zhao, X., Ren, R., Wang, Y., Su, C., Chen, J., & Ma, X. (2022). Integration of pharmacodynamics and metabolomics reveals the therapeutic effects of 6‐acetylacteoside on ovariectomy‐induced osteoporosis mice. Phytomedicine, 106, 154399. https://doi.org/10.1016/j.phymed.2022.154399
Liu, X., Wang, Z., Song, X., Chang, X., Zu, E., Ma, X., Sukegawa, M., Liu, D., & Wang, D. O. (2021). Crocetin alleviates Ovariectomy‐induced metabolic dysfunction through regulating estrogen receptor β. Journal of Agricultural and Food Chemistry, 69(49), 14824–14839. https://doi.org/10.1021/acs.jafc.1c04570
Lü, J. M., Jiang, J., Jamaluddin, M. S., Liang, Z., Yao, Q., & Chen, C. (2019). Ginsenoside Rb1 blocks ritonavir‐induced oxidative stress and eNOS downregulation through activation of estrogen receptor‐beta and upregulation of SOD in human endothelial cells. International Journal of Molecular Sciences, 20(2), 294. https://doi.org/10.3390/ijms20020294
Lu, X. Z., Wang, J. H., Wu, X., Zhou, L., Wang, L., Zhang, X. W., Cao, K. J., & Huang, J. (2008). Ginsenoside Rg1 promotes bone marrow stromal cells proliferation via the activation of the estrogen receptor‐mediated signaling pathway. Acta Pharmacologica Sinica, 29(10), 1209–1214. https://doi.org/10.1111/j.1745-7254.2008.00874.x
Maffei, S., & Guiducci, L. (2022). Effect of ospemifene on densitometric and plasma bone metabolism biomarkers in postmenopausal women reporting vulvar and vaginal atrophy (VVA). Journal of Clinical Medicine, 11(21), 6316. https://doi.org/10.3390/jcm11216316
Mao, C., Yang, Z. Y., He, B. F., Liu, S., Zhou, J. H., Luo, R. C., Chen, Q., & Tang, J. L. (2012). Toremifene versus tamoxifen for advanced breast cancer. Cochrane Database of Systematic Reviews, 2012(7), Cd008926. https://doi.org/10.1002/14651858.CD008926.pub2
McClung, M. R., Siris, E., Cummings, S., Bolognese, M., Ettinger, M., Moffett, A., Emkey, R., Day, W., Somayaji, V., & Lee, A. (2006). Prevention of bone loss in postmenopausal women treated with lasofoxifene compared with raloxifene. Menopause, 13(3), 377–386. https://doi.org/10.1097/01.gme.0000188736.69617.4f
Meyer, M. R., & Barton, M. (2016). Estrogens and coronary artery disease: New clinical perspectives. Advances in Pharmacology, 77, 307–360. https://doi.org/10.1016/bs.apha.2016.05.003
Miao, J., Jing, Y., Chi, Z., Liu, B., & Lu, A. (2010). Clinical studies with traditional Chinese medicine in the past decade and future Research and Development. Planta Medica, 76(17), 2048–2064.
Mir, M. A., Ganai, S. A., Mansoor, S., Jan, S., Mani, P., Masoodi, K. Z., Amin, H., Rehman, M. U., & Ahmad, P. (2020). Isolation, purification and characterization of naturally derived crocetin beta‐d‐glucosyl ester from Crocus sativus L. against breast cancer and its binding chemistry with ER‐alpha/HDAC2. Saudi Journal of Biological Sciences, 27(3), 975–984. https://doi.org/10.1016/j.sjbs.2020.01.018
Mishra, A., Srivastava, A., Pateriya, A., Tomar, M. S., Mishra, A. K., & Shrivastava, A. (2021). Metabolic reprograming confers tamoxifen resistance in breast cancer. Chemico‐Biological Interactions, 347, 109602. https://doi.org/10.1016/j.cbi.2021.109602
Mok, S. K., Chen, W. F., Lai, W. P., Leung, P. C., Wang, X. L., Yao, X. S., & Wong, M. S. (2010). Icariin protects against bone loss induced by oestrogen deficiency and activates oestrogen receptor‐dependent osteoblastic functions in UMR 106 cells. British Journal of Pharmacology, 159(4), 939–949.
Moshi, M. R., Nicolopoulos, K., Stringer, D., Ma, N., Jenal, M., & Vreugdenburg, T. (2023). The clinical effectiveness of Denosumab (Prolia®) for the treatment of osteoporosis in postmenopausal women, compared to bisphosphonates, selective estrogen receptor modulators (SERM), and placebo: A systematic review and network meta‐analysis. Calcified Tissue International, 112(6), 631–646. https://doi.org/10.1007/s00223-023-01078-z
Motlani, G., Motlani, V., Acharya, N., Dave, A., Pamnani, S., Somyani, D., & Agrawal, S. (2023). Novel advances in the role of selective estrogen receptor modulators in hormonal replacement therapy: A paradigm shift. Cureus, 15(11), e49079. https://doi.org/10.7759/cureus.49079
Motlani, V., Motlani, G., Pamnani, S., Sahu, A., & Acharya, N. (2023). Endocrine changes in postmenopausal women: A comprehensive view. Cureus, 15(12), e51287. https://doi.org/10.7759/cureus.51287
Nakatoh, S. (2018). Effect of osteoporosis medication on changes in bone mineral density and bone turnover markers after 24‐month administration of daily teriparatide: Comparison among minodronate, raloxifene, and eldecalcitol. Journal of Bone and Mineral Metabolism, 36(2), 221–228. https://doi.org/10.1007/s00774-017-0829-4
Namba, S., Yokota, H., Mukai, H., Hashiba, J., Kogayo, N., Nakao, T., Sugiyama, A., Ogaya, E., Aotsuka, Y., Kuwabara, S., & Uno, T. (2024). Neurosarcoidosis with enlargement of the dorsal root ganglia: A case report. Radiology Case Reports, 19(5), 1718–1721. https://doi.org/10.1016/j.radcr.2024.01.032
Nilsson, S., & Koehler, K. F. (2005). Oestrogen receptors and selective oestrogen receptor modulators: Molecular and cellular pharmacology. Basic & Clinical Pharmacology & Toxicology, 96(1), 15–25. https://doi.org/10.1111/j.1742-7843.2005.pto960103.x
O'Donnell, E. F., Koch, D. C., Bisson, W. H., Jang, H. S., & Kolluri, S. K. (2014). The aryl hydrocarbon receptor mediates raloxifene‐induced apoptosis in estrogen receptor‐negative hepatoma and breast cancer cells. Cell Death & Disease, 5(1), e1038. https://doi.org/10.1038/cddis.2013.549
Ou, L., Kang, W., Liang, Z., Gao, F., Dong, T., Wei, P., & Li, M. (2021). Investigation of anti‐osteoporosis mechanisms of rehmanniae radix preparata based on network pharmacology and experimental verification. Journal of Orthopaedic Surgery and Research, 16(1), 599. https://doi.org/10.1186/s13018-021-02751-5
Pacifici, R. (1996). Estrogen, cytokines, and pathogenesis of postmenopausal osteoporosis. Journal of Bone and Mineral Research, 11(8), 1043–1051. https://doi.org/10.1002/jbmr.5650110802
Park, K. S., Kim, H., Kim, H. J., Lee, K. I., Lee, S. Y., & Kim, J. (2022). Paeoniflorin alleviates skeletal muscle atrophy in ovariectomized mice through the ERα/NRF1 mitochondrial biogenesis pathway. Pharmaceuticals, 2022, 15390.
Patel, H. K., & Bihani, T. (2018). Selective estrogen receptor modulators (SERMs) and selective estrogen receptor degraders (SERDs) in cancer treatment. Pharmacology & Therapeutics, 186, 1–24. https://doi.org/10.1016/j.pharmthera.2017.12.012
Peek, G. W., & Tollefsbol, T. O. (2016). Combinatorial PX‐866 and Raloxifene decrease Rb phosphorylation, cyclin E2 transcription, and proliferation of MCF‐7 breast cancer cells. Journal of Cellular Biochemistry, 117(7), 1688–1696. https://doi.org/10.1002/jcb.25462
Peng, M. F., Tian, S., Song, Y. G., Li, C. X., Miao, M. S., Ren, Z., & Li, M. (2021). Effects of total flavonoids from Eucommia ulmoides Oliv. Leaves on polycystic ovary syndrome with insulin resistance model rats induced by letrozole combined with a high‐fat diet. Journal of Ethnopharmacology, 273, 113947. https://doi.org/10.1016/j.jep.2021.113947
Peng, W. X., Koirala, P., Zhou, H., Jiang, J., Zhang, Z., Yang, L., & Mo, Y. Y. (2021). Lnc‐DC promotes estrogen independent growth and tamoxifen resistance in breast cancer. Cell Death & Disease, 12(11), 1000. https://doi.org/10.1038/s41419-021-04288-1
Pinkerton, J. V., & Conner, E. A. (2019). Beyond estrogen: Advances in tissue selective estrogen complexes and selective estrogen receptor modulators. Climacteric, 22(2), 140–147. https://doi.org/10.1080/13697137.2019.1568403
Pinkerton, J. V., Harvey, J. A., Lindsay, R., Pan, K., Chines, A. A., Mirkin, S., & Archer, D. F. (2014). Effects of bazedoxifene/conjugated estrogens on the endometrium and bone: A randomized trial. The Journal of Clinical Endocrinology and Metabolism, 99(2), E189–E198. https://doi.org/10.1210/jc.2013-1707
Pinkerton, J. V., & Thomas, S. (2014). Use of SERMs for treatment in postmenopausal women. Journal of Steroid Biochemistry & Molecular Biology, 142, 142–154. https://doi.org/10.1016/j.jsbmb.2013.12.011
Pru, J. K. (2013). Benefits and recently identified limitations of bazedoxifene acetate for postmenopausal symptoms. Menopause, 20(3), 252–253. https://doi.org/10.1097/GME.0b013e318286cc45
Przerwa, F., Uzar, I., Bogacz, A., Kotrych, K., Sulikowski, T., Wolek, M., Kamiński, A., Ziętek, P., & Czerny, B. (2023). Osteoprotegerin gene as a biomarker in the development of osteoporosis in postmenopausal women. Biomedicine, 11(12), 3218. https://doi.org/10.3390/biomedicines11123218
Qiu, X., Xiao, X., Ren, A., Xiao, M., Tian, H., Ling, W., Wang, M., Li, Y., & Zhao, Y. (2020). Effects of PXD101 and embryo aggregation on the in vitro development of mouse parthenogenetic embryos. Cellular Reprogramming, 22(1), 14–21. https://doi.org/10.1089/cell.2019.0038
Qu, Q., Zheng, H., Dahllund, J., Laine, A., Cockcroft, N., Peng, Z., Koskinen, M., Hemminki, K., Kangas, L., Väänänen, K., & Härkönen, P. (2000). Selective estrogenic effects of a novel triphenylethylene compound, FC1271a, on bone, cholesterol level, and reproductive tissues in intact and ovariectomized rats. Endocrinology, 141(2), 809–820. https://doi.org/10.1210/endo.141.2.7342
Rahn, D. D., Carberry, C., Sanses, T. V., Mamik, M. M., Ward, R. M., Meriwether, K. V., Olivera, C. K., Abed, H., Balk, E. M., & Murphy, M. (2014). Vaginal estrogen for genitourinary syndrome of menopause: A systematic review. Obstetrics and Gynecology, 124(6), 1147–1156. https://doi.org/10.1097/aog.0000000000000526
Recker, R. R., Mitlak, B. H., Ni, X., & Krege, J. H. (2011). Long‐term raloxifene for postmenopausal osteoporosis. Current Medical Research and Opinion, 27(9), 1755–1761. https://doi.org/10.1185/03007995.2011.606312
Reinbolt, R. E., Mangini, N., Hill, J. L., Levine, L. B., Dempsey, J. L., Singaravelu, J., Koehler, K. A., Talley, A., & Lustberg, M. B. (2015). Endocrine therapy in breast cancer: The neoadjuvant, adjuvant, and metastatic approach. Seminars in Oncology Nursing, 31(2), 146–155. https://doi.org/10.1016/j.soncn.2015.02.002
Ryu, K. J., Kim, M. S., Lee, J. Y., Nam, S., Jeong, H. G., Kim, T., & Park, H. (2022). Risk of endometrial polyps, hyperplasia, carcinoma, and uterine cancer after tamoxifen treatment in premenopausal women with breast cancer. JAMA Network Open, 5(11), e2243951. https://doi.org/10.1001/jamanetworkopen.2022.43951
Sakamoto, S., Mitamura, T., Iwasawa, M., Kitsunai, H., Shindou, K., Yagishita, Y., Zhou, Y. F., & Sassa, S. (1998). Conservative management for perimenopausal women with uterine leiomyomas using Chinese herbal medicines and synthetic analogs of gonadotropin‐releasing hormone. In Vivo, 12(3), 333–337.
Sánchez‐Guerrero, J., Liang, M. H., Karlson, E. W., Hunter, D. J., & Colditz, G. A. (1995). Postmenopausal estrogen therapy and the risk for developing systemic lupus erythematosus. Annals of Internal Medicine, 122(6), 430–433. https://doi.org/10.7326/0003-4819-122-6-199503150-00005
Santen, R. J., Stuenkel, C. A., Davis, S. R., Pinkerton, J. V., Gompel, A., & Lumsden, M. A. (2017). Managing menopausal symptoms and associated clinical issues in breast cancer survivors. The Journal of Clinical Endocrinology and Metabolism, 102(10), 3647–3661. https://doi.org/10.1210/jc.2017-01138
Schiavi, M. C., Cignini, P., Zullo, M. A., Luffarelli, P., Morgani, C., Yacoub, V., Carletti, V., Bisogni, F., Galanti, F., Pinto, A. D., Miriello, D., Rago, R., Valensise, H. C., & Palazzetti, P. L. (2023). Sexual function analysis and clitoral vascularization in postmenopausal women with genitourinary syndrome treated with ospemifene. Minerva Obstetrics and Gynecology, 75(2), 138–144. https://doi.org/10.23736/s2724-606x.21.04862-4
Seli, E., Selam, B., Mor, G., Kayisli, U. A., Pehlivan, T., & Arici, A. (2001). Estradiol regulates monocyte chemotactic protein‐1 in human coronary artery smooth muscle cells: A mechanism for its antiatherogenic effect. Menopause, 8(4), 296–301. https://doi.org/10.1097/00042192-200107000-00013
Shih, C., Liao, C., Su, Y., Tsai, C., & Lin, J. (2012). Gender differences in traditional Chinese medicine use among adults in Taiwan. PLoS One, 7, e32540. https://doi.org/10.1371/journal.pone.0032540
Soares, C. N., Poitras, J. R., & Prouty, J. (2003). Effect of reproductive hormones and selective estrogen receptor modulators on mood during menopause. Drugs & Aging, 20(2), 85–100. https://doi.org/10.2165/00002512-200320020-00001
Solipuram, V., Pokharel, K., & Ihedinmah, T. (2021). Pulmonary embolism as a rare complication of clomiphene therapy: A case report and literature review. Case Reports in Endocrinology, 2021, 9987830. https://doi.org/10.1155/2021/9987830
Son, W. H., Park, H. T., Jeon, B. H., & Ha, M. S. (2023). Moderate intensity walking exercises reduce the body mass index and vascular inflammatory factors in postmenopausal women with obesity: A randomized controlled trial. Scientific Reports, 13(1), 20172. https://doi.org/10.1038/s41598-023-47403-2
Song, Y., Santen, R. J., Wang, J. P., & Yue, W. (2012). Effects of the conjugated equine estrogen/bazedoxifene tissue‐selective estrogen complex (TSEC) on mammary gland and breast cancer in mice. Endocrinology, 153(12), 5706–5715. https://doi.org/10.1210/en.2012-1583
Stevenson, J. C., Tsiligiannis, S., & Panay, N. (2019). Cardiovascular risk in perimenopausal women. Current Vascular Pharmacology, 17(6), 591–594. https://doi.org/10.2174/1570161116666181002145340
Stuenkel, C. A. (2015). Menopausal hormone therapy: Current considerations. Endocrinology and Metabolism Clinics of North America, 44(3), 565–585. https://doi.org/10.1016/j.ecl.2015.05.006
Sui, J. Q., Xie, K. P., Zou, W., & Xie, M. J. (2014). Emodin inhibits breast cancer cell proliferation through the ERα‐MAPK/Akt‐cyclin D1/Bcl‐2 signaling pathway. Asian Pacific Journal of Cancer Prevention, 15(15), 6247–6251. https://doi.org/10.7314/apjcp.2014.15.15.6247
Sumner, B. E. H., Grant, K. E., Rosie, R., Hegele‐Hartung, C., Fritzemeier, K. H., & Fink, G. (1999). Effects of tamoxifen on serotonin transporter and 5‐hydroxytryptamine(2A) receptor binding sites and mRNA levels in the brain of ovariectomized rats with or without acute estradiol replacement. Molecular Brain Research, 73(1–2), 119–128.
Sun, K., Mei, W., Mo, S., Xin, L., Lei, X., Huang, M., Chen, Q., Han, L., & Zhu, X. (2019). Lead exposure inhibits osteoblastic differentiation and inactivates the canonical Wnt signal and recovery by icaritin in MC3T3‐E1 subclone 14 cells. Chemico‐Biological Interactions, 303, 7–13. https://doi.org/10.1016/j.cbi.2019.01.039
Sundell, M., Spetz Holm, A. C., Fredrikson, M., Hammar, M., Hoffmann, M., & Brynhildsen, J. (2022). Pulmonary embolism in menopausal hormone therapy: A population‐based register study. Climacteric, 25(6), 615–621. https://doi.org/10.1080/13697137.2022.2127352
Swan, V. J., Hamilton, C. J., & Jamal, S. A. (2010). Lasofoxifene in osteoporosis and its place in therapy. Advances in Therapy, 27(12), 917–932. https://doi.org/10.1007/s12325-010-0081-y
Takami, M., & Shimada, H. (2010). Effects of SERMs on bone health. SERM and metabolic markers of bone. Clinical Calcium, 20(3), 365–371.
Tan, X., Wen, F., Yang, W., Xie, J. Y., Ding, L. L., & Mo, Y. X. (2019). Comparative efficacy and safety of pharmacological interventions for osteoporosis in postmenopausal women: A network meta‐analysis (Chongqing, China). Menopause, 26(8), 929–939. https://doi.org/10.1097/gme.0000000000001321
Tao, Z., Liu, J., Jiang, Y., Gong, L., & Yang, B. (2017). Synthesis of prenylated flavonols and their potents as estrogen receptor modulator. Scientific Reports, 7(1), 12445. https://doi.org/10.1038/s41598-017-12640-9
Taylor, H. S. (2009). Designing the ideal selective estrogen receptor modulator‐an achievable goal? Menopause, 16(3), 609–615.
Tian, S., Miao, M. S., Li, X. M., Bai, M., Wu, Y. Y., & Wei, Z. Z. (2019). Study on neuroendocrine‐immune function of phenylethanoid glycosides of desertliving cistanche herb in perimenopausal rat model. Journal of Ethnopharmacology, 238, 111884. https://doi.org/10.1016/j.jep.2019.111884
Tseng, S. H., Sung, C. H., Chen, L. G., Lai, Y. J., Chang, W. S., Sung, H. C., & Wang, C. C. (2014). Comparison of chemical compositions and osteoprotective effects of different sections of velvet antler. Journal of Ethnopharmacology, 151(1), 352–360. https://doi.org/10.1016/j.jep.2013.10.060
Umland, E. M., Karel, L., & Santoro, N. (2016). Bazedoxifene and conjugated equine estrogen: A combination product for the management of vasomotor symptoms and osteoporosis prevention associated with menopause. Pharmacotherapy, 36(5), 548–561. https://doi.org/10.1002/phar.1749
Ungvari, Z., Bagi, Z., Feher, A., Recchia, F. A., Sonntag, W. E., Pearson, K., de Cabo, R., & Csiszar, A. (2010). Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. American Journal of Physiology. Heart and Circulatory Physiology, 299(1), H18–H24. https://doi.org/10.1152/ajpheart.00260.2010
Vogel, V. G. (2011). Update on raloxifene: Role in reducing the risk of invasive breast cancer in postmenopausal women. Breast Cancer (Dove Med Press), 3, 127–137. https://doi.org/10.2147/bctt.S11288
Walsh, B. W., Paul, S., Wild, R. A., Dean, R. A., Tracy, R. P., Cox, D. A., & Anderson, P. W. (2000). The effects of hormone replacement therapy and raloxifene on C‐reactive protein and homocysteine in healthy postmenopausal women: A randomized, controlled trial. The Journal of Clinical Endocrinology and Metabolism, 85(1), 214–218.
Wang, D., & Wang, X. (2022). Diosgenin and its analogs: Potential protective agents against atherosclerosis. Drug Design, Development and Therapy, 16, 2305–2323. https://doi.org/10.2147/dddt.S368836
Wang, F. G., Sun, Y., Cao, J., Shen, X. R., Liu, F. W., Song, S. S., Hou, X. Q., & Yin, L. (2023). Effects of Danggui‐Shaoyao‐san on central neuroendocrine and pharmacokinetics in female ovariectomized rats. Journal of Ethnopharmacology, 316, 116609. https://doi.org/10.1016/j.jep.2023.116609
Wang, G., Li, Y., Lei, C., Lei, X., & Zhang, R. (2021). Quercetin exerts antidepressant and cardioprotective effects in estrogen receptor α‐deficient female mice via BDNF‐AKT/ERK1/2 signaling. The Journal of Steroid Biochemistry and Molecular Biology, 206, 105795.
Wang, K., Shen, L., Tian, W., & Zhang, S. (2022). Comparison of changes in lipid profiles of premenopausal women with early‐stage breast cancer treated with different endocrine therapies. Scientific Reports, 12(1), 22650. https://doi.org/10.1038/s41598-022-27008-x
Wang, W., Zhang, L. M., Guo, C., & Han, J. F. (2020). Resveratrol promotes osteoblastic differentiation in a rat model of postmenopausal osteoporosis by regulating autophagy. Nutrition & Metabolism (London), 17, 29. https://doi.org/10.1186/s12986-020-00449-9
Wang, X. N., Simmons, H. A., Salatto, C. T., Cosgrove, P. G., & Thompson, D. D. (2006). Lasofoxifene enhances vaginal mucus formation without causing hypertrophy and increases estrogen receptor beta and androgen receptor in rats. Menopause, 13(4), 609–620. https://doi.org/10.1097/01.gme.0000227337.73738.c9
Wang, Z., Zhang, G., Le, Y., Ju, J., Zhang, P., Wan, D., Zhao, Q., Jin, G., Su, H., Liu, J., Feng, J., Fu, Y., & Hou, R. (2020). Quercetin promotes human epidermal stem cell proliferation through the estrogen receptor/β‐catenin/c‐Myc/cyclin A2 signaling pathway. Acta Biochimica et Biophysica Sinica (Shanghai), 52(10), 1102–1110. https://doi.org/10.1093/abbs/gmaa091
Wang, Z., Zhang, X., Wang, H., Qi, L., & Lou, Y. (2007). Neuroprotective effects of icaritin against beta amyloid‐induced neurotoxicity in primary cultured rat neuronal cells via estrogen‐dependent pathway. Neuroscience, 145(3), 911–922. https://doi.org/10.1016/j.neuroscience.2006.12.059
Wattanathorn, J., Somboonporn, W., Sungkamanee, S., Thukummee, W., & Muchimapura, S. (2018). A double‐blind placebo‐controlled randomized trial evaluating the effect of polyphenol‐rich herbal congee on bone turnover markers of the perimenopausal and menopausal women. Oxidative Medicine and Cellular Longevity, 2018, 2091872. https://doi.org/10.1155/2018/2091872
Wei, M., Lu, Y., Liu, D., & Ru, W. (2014). Ovarian failure‐resistant effects of catalpol in aged female rats. Biological & Pharmaceutical Bulletin, 37(9), 1444–1449. https://doi.org/10.1248/bpb.b14-00064
Wei, M., Mahady, G. B., Liu, D., Zheng, Z. S., & Lu, Y. (2016). Astragalin, a flavonoid from Morus alba (mulberry) increases endogenous estrogen and progesterone by inhibiting ovarian granulosa cell apoptosis in an aged rat model of menopause. Molecules, 21(5), 675. https://doi.org/10.3390/molecules21050675
Wei, Q., Wang, B., Hu, H., Xie, C., Ling, L., Gao, J., & Cao, Y. (2020). Icaritin promotes the osteogenesis of bone marrow mesenchymal stem cells via the regulation of sclerostin expression. International Journal of Molecular Medicine, 45(3), 816–824. https://doi.org/10.3892/ijmm.2020.4470
Wissink, S., Burg, B. V. D., Katzenellenbogen, B. S., & Saag, P. T. V. D. (2001). Synergistic activation of the serotonin‐1A receptor by nuclear factor‐kappa B and estrogen. Molecular Endocrinology, 15(4), 543.
Xie, Q. F., Xie, J. H., Dong, T. T., Su, J. Y., Cai, D. K., Chen, J. P., Liu, L. F., Li, Y. C., Lai, X. P., Tsim, K. W., & Su, Z. R. (2012). Effect of a derived herbal recipe from an ancient Chinese formula, Danggui Buxue Tang, on ovariectomized rats. Journal of Ethnopharmacology, 144(3), 567–575. https://doi.org/10.1016/j.jep.2012.09.041
Xin, D., Wang, H., Yang, J., Su, Y. F., Fan, G. W., Wang, Y. F., Zhu, Y., & Gao, X. M. (2010). Phytoestrogens from Psoralea corylifolia reveal estrogen receptor‐subtype selectivity. Phytomedicine, 17(2), 126–131. https://doi.org/10.1016/j.phymed.2009.05.015
Xu, Y., Li, X., Chen, T., Qu, Y. K., Zheng, H. X., Zhang, Z. J., Zhao, Y., & Lin, N. (2019). Radix Paeoniae Alba increases serum estrogen level and up‐regulates estrogen receptor expression in uterus and vagina of immature/ovariectomized mice. Phytotherapy Research, 33(1), 117–129. https://doi.org/10.1002/ptr.6205
Yamada, N., Araki, H., & Yoshimura, H. (2011). Identification of antidepressant‐like ingredients in ginseng root (Panax ginseng C.A. Meyer) using a menopausal depressive‐like state in female mice: Participation of 5‐HT2A receptors. Psychopharmacology, 216(4), 589–599. https://doi.org/10.1007/s00213-011-2252-1
Yan, F. X., Zhu, X. D., Wang, S., Yao, W., Xie, Y. Y., Zhou, R. Q., Chen, Y. H., Wu, Y., & Huang, L. P. (2022). Mechanism analysis of repeatedly steamed and sundried Rehmanniae radix Praeparata in delaying brain aging in ovariectomized mice based on proteomics. Zhongguo Zhong Yao Za Zhi, 47(1), 141–150. https://doi.org/10.19540/j.cnki.cjcmm.20211025.402
Yan, M. Z., Xu, Y., Gong, Y. X., Liu, J. M., Lu, S. Y., Huang, L., Wang, Z. G., Zhao, Y. J., & Pang, X. F. (2010). Raloxifene inhibits bone loss and improves bone strength through an Opg‐independent mechanism. Endocrine, 37(1), 55–61. https://doi.org/10.1007/s12020-009-9267-y
Yang, F., Yuan, P. W., Hao, Y. Q., & Lu, Z. M. (2014). Emodin enhances osteogenesis and inhibits adipogenesis. BMC Complementary and Alternative Medicine, 14, 74. https://doi.org/10.1186/1472-6882-14-74
Yang, F. L., Hu, K. Q., Wang, X., Liu, Z. M., Hu, Q., Li, J. F., & He, H. (2011). Combination of raloxifene, aspirin and estrogen as novel paradigm of hormone replacement therapy in rabbit model of menopause. Acta Pharmacologica Sinica, 32(8), 1031–1037. https://doi.org/10.1038/aps.2011.87
Yang, G., Zhuo, J., Lin, Y., Zhang, M., Liu, L., Chen, X., & Gao, R. (2019). Ginsenoside Rb1 prevents dysfunction of endothelial cells by suppressing inflammatory response and apoptosis in the high‐fat diet plus balloon catheter‐injured rabbit model via the G protein‐coupled estrogen receptor‐mediated phosphatidylinositol 3‐kinases (PI3K)/Akt pathway. Medical Science Monitor, 25, 7407–7417. https://doi.org/10.12659/msm.912986
Yang, L., Chen, Q., Wang, F., & Zhang, G. (2011). Antiosteoporotic compounds from seeds of Cuscuta chinensis. Journal of Ethnopharmacology, 135(2), 553–560. https://doi.org/10.1016/j.jep.2011.03.056
Yang, L., Lu, D., Guo, J., Meng, X., Zhang, G., & Wang, F. (2013). Icariin from Epimedium brevicornum maxim promotes the biosynthesis of estrogen by aromatase (CYP19). Journal of Ethnopharmacology, 145(3), 715–721. https://doi.org/10.1016/j.jep.2012.11.031
Yang, Q., Wang, C., Jin, Y., Ma, X., Xie, T., Wang, J., Liu, K., & Sun, H. (2019). Disocin prevents postmenopausal atherosclerosis in ovariectomized LDLR−/− mice through a PGC‐1α/ERα pathway leading to promotion of autophagy and inhibition of oxidative stress, inflammation and apoptosis. Pharmacological Research, 148, 104414. https://doi.org/10.1016/j.phrs.2019.104414
Yang, Q., Wang, C., Jin, Y., Ma, X., Xie, T., Wang, J., Liu, K., & Sun, H. (2020). Corrigendum to “Disocin prevents postmenopausal atherosclerosis in ovariectomized LDLR−/mice through a PGC‐1α/ERα pathway leading to promotion of autophagy and inhibition of oxidative stress, inflammation and apoptosis” [Pharmacol. Res. 148 (2019) 104414]. Pharmacological Research, 153, 104523. https://doi.org/10.1016/j.phrs.2019.104523
Yao, G., Bai, Z., Niu, J., Zhang, R., Lu, Y., Gao, T., & Wang, H. (2022). Astragalin attenuates depression‐like behaviors and memory deficits and promotes M2 microglia polarization by regulating IL‐4R/JAK1/STAT6 signaling pathway in a murine model of perimenopausal depression. Psychopharmacology, 239(8), 2421–2443. https://doi.org/10.1007/s00213-022-06133-5
Yong, E. L., Cheong, W. F., Huang, Z., Thu, W. P. P., Cazenave‐Gassiot, A., Seng, K. Y., & Logan, S. (2021). Randomized, double‐blind, placebo‐controlled trial to examine the safety, pharmacokinetics and effects of Epimedium prenylflavonoids, on bone specific alkaline phosphatase and the osteoclast adaptor protein TRAF6 in post‐menopausal women. Phytomedicine, 91, 153680. https://doi.org/10.1016/j.phymed.2021.153680
Yuk, J. S. (2023). Endometrial cancer risk with menopausal hormone therapy: Health insurance database in South Korea‐based cohort study. International Journal of Gynaecology and Obstetrics, 162(2), 502–513. https://doi.org/10.1002/ijgo.14753
Zargar, S. & WaniT. A. (2021). Protective role of quercetin in carbon tetrachloride induced toxicity in rat brain: Biochemical, spectrophotometric assays and computational approach. Molecules, 26(24), 7526. https://doi.org/10.3390/molecules26247526
Zaychenko, G., Belenichev, I., Hnatiuk, V., Doroshenko, A., Sinitsyna, O., Sulaieva, O., Falalyeyeva, T., & Kobyliak, N. (2023). Protective effect of vaginal resveratrol administration on joint tissues in ovariectomized rats: Targeting mTOR and сaspase 3. Biomedicine & Pharmacotherapy, 165, 115176. https://doi.org/10.1016/j.biopha.2023.115176
Zeng, M., Zhang, L., Li, M., Zhang, B., Zhou, N., Ke, Y., Feng, W., & Zheng, X. (2018). Estrogenic effects of the extracts from the Chinese yam (Dioscorea opposite Thunb.) and its effective compounds in vitro and in vivo. Molecules, 23(2), 11. https://doi.org/10.3390/molecules23020011
Zhang, B., Zhou, W. J., Gu, C. J., Wu, K., Yang, H. L., Mei, J., Yu, J. J., Hou, X. F., Sun, J. S., Xu, F. Y., Li, D. J., Jin, L. P., & Li, M. Q. (2018). The ginsenoside PPD exerts anti‐endometriosis effects by suppressing estrogen receptor‐mediated inhibition of endometrial stromal cell autophagy and NK cell cytotoxicity. Cell Death & Disease, 9(5), 574. https://doi.org/10.1038/s41419-018-0581-2
Zhang, C., Peng, J., Wu, S., Jin, Y., Xia, F., Wang, C., Liu, K., Sun, H., & Liu, M. (2014). Dioscin promotes osteoblastic proliferation and differentiation via Lrp5 and ER pathway in mouse and human osteoblast‐like cell lines. Journal of Biomedical Science, 21(1), 30. https://doi.org/10.1186/1423-0127-21-30
Zhang, T., Zhong, S., Hou, L., Wang, Y., Xing, X., Guan, T., Zhang, J., & Li, T. (2020). Computational and experimental characterization of estrogenic activities of 20(S, R)‐protopanaxadiol and 20(S, R)‐protopanaxatriol. Journal of Ginseng Research, 44(5), 690–696. https://doi.org/10.1016/j.jgr.2018.05.001
Zhang, X., Peng, B., Fan, M., Bian, Z., & Chen, Z. (2007). The effect of estrogen deficiency on receptor activator of nuclear factor kappa B ligand and osteoprotegerin synthesis in periapical lesions induced in rats. Journal of Endodontia, 33(9), 1053–1056. https://doi.org/10.1016/j.joen.2007.04.005
Zhang, X., Zhao, W., Wang, Y., Lu, J., & Chen, X. (2016). The chemical constituents and bioactivities of Psoralea corylifolia Linn.: A review. The American Journal of Chinese Medicine, 44(1), 35–60. https://doi.org/10.1142/s0192415x16500038
Zhou, L., Chui‐Wa, P. C., Ka‐Ying, W., Cao, S., Yu, W., Dong, X., Yuk‐Wai, L. W., Zhang, Y., & Man‐Sau, W. (2019). Prenylflavonoid icariin induces ERE‐independent estrogenic responses in a tissue selective manner. Journal of the Endocrine Society, 4, bvz025.
Zhou, L., Poon, C. C., Wong, K. Y., Cao, S., Dong, X., Zhang, Y., & Wong, M. S. (2021). Icariin ameliorates estrogen‐deficiency induced bone loss by enhancing IGF‐I signaling via its crosstalk with non‐genomic ERα signaling. Phytomedicine, 82, 153413. https://doi.org/10.1016/j.phymed.2020.153413
Zhou, S., Gao, Y., An, J., Guo, L., Jiang, W., Ou, X., Qin, L., Zhou, T., & Yuan, Q. S. (2024). Rhizopus oryzae causes the leaf rot disease of Epimedium sagittatum in Guizhou, China. Plant Disease. https://doi.org/10.1094/pdis-10-23-2241-pdn
Zhou, X., Wang, S., Sun, H., & Wu, B. (2015). Sulfonation of raloxifene in HEK293 cells overexpressing SULT1A3: Involvement of breast cancer resistance protein (BCRP/ABCG2) and multidrug resistance‐associated protein 4 (MRP4/ABCC4) in excretion of sulfate metabolites. Drug Metabolism and Pharmacokinetics, 30(6), 425–433. https://doi.org/10.1016/j.dmpk.2015.09.001
Zhou, Y. X., Gong, X. H., Zhang, H., & Peng, C. (2020). A review on the pharmacokinetics of paeoniflorin and its anti‐inflammatory and immunomodulatory effects. Biomedicine & Pharmacotherapy, 130, 110505. https://doi.org/10.1016/j.biopha.2020.110505
Zhu, H., You, J., Wen, Y., Jia, L., & Chen, J. (2021). Tumorigenic risk of Angelica sinensis on ER‐positive breast cancer growth through ER‐induced stemness in vitro and in vivo. Journal of Ethnopharmacology, 280, 114415. https://doi.org/10.1016/j.jep.2021.114415
Zhu, Y., Yang, X., Wang, Y., & Zhu, X. (2023). Assessment of knowledge, understanding and awareness of Chinese women clinical staff towards menopause hormone therapy: A survey study. Journal of Obstetrics and Gynaecology, 43(1), 2171779. https://doi.org/10.1080/01443615.2023.2171779
Zimmerman, M. A., Hutson, D. D., Mauvais‐Jarvis, F., & Lindsey, S. H. (2019). Bazedoxifene‐induced vasodilation and inhibition of vasoconstriction is significantly greater than estradiol. Menopause, 26(2), 172–181. https://doi.org/10.1097/gme.0000000000001195